Pendulum Glucose Control (PGC)
Phase 1Biologic
Pendulum Glucose Control (PGC) is one of 51 biologic programs targeting Toxicity. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Toxicity
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyApproved
Aldactone
PfizerApproved
Zyvox
PfizerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Rayos
RRoxane Laboratories
Approved
Ativan
BBausch Health Americas, Inc.
Approved
Jardiance
Boehringer IngelheimApproved
Merrem
BB. Braun Medical Inc.
Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Cincinnati